Bristol-Myers Squibb Company (BMY) Q1 2022 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 2.5%

Bristol Myers Squibb's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 2.5% following the announcement, likely due to the lack of revenue details and guidance. Investors may be cautious given the uncertainties in the market and the absence of forward-looking statements from management.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.96	N/A	+2.35%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in their pipeline and future growth. However, they acknowledged challenges in the current market environment.

Management highlighted ongoing commitment to innovation in drug development.

They emphasized the importance of maintaining strong operational performance.

Bristol Myers Squibb Beats on EPS, Stock Down 2.5%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 2.5%

Key numbers

Management commentary